Detalhe da pesquisa
1.
Impact of disease duration and ß-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial.
Diabetes Obes Metab
; 22(9): 1567-1576, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32323437